Publications
2023-2025
Chen F, Li H, Wang Y, Tang X, Lin K, Li Q, Meng C, Shi W, Leo J, Liang X, Zhang J, Van V, Mahmud I, Wei B, Lorenzi P, Raso M, Aparicio A, Lu Y, Frigo D, Gan B, Zhao D*. CHD1 loss reprograms SREBP2-driven cholesterol synthesis to fuel androgen-responsive growth and castration resistance in SPOP-mutated prostate tumors. Nature Cancer. 2025 May 13. doi: 10.1038/s43018-025-00952-z. PMID: 40360905n
Meng C, Lin K, Shi W, Teng H, DeBruine A, Wang Y, Chen F, Leo J, Zhang J, Van V, Maldonado K, Gan B, Ma L, Lu Y*, Zhao D*. Histone Methyltransferase ASH1L Primes Metastases and Metabolic Reprogramming of Macrophages in the Bone Niche. Nature Communications. 2025 May 20. doi: 10.1038/s41467-025-59381-2. PMID: 40394007. PMCID: PMC12092585.
Chan E, Chhabra Y, Dixon K, Durbin A, Färkkilä A, Jeyasekharan A, Keckesova Z, Prensner J, Wagenblast E, Xie S, Zhao D. Insights on future directions in cancer research from the 2025 AACR NextGen Stars. Cancer Discovery. 2025 Apr 2;15(4):678-684. doi: 10.1158/2159-8290.CD-25-0239. PMID: 40170536 .
Shi W, Wang Y, Zhao Y, Kim JJ, Li H, Meng C, Chen F, Zhang J, Mak DH, Van V, Leo J, St Croix B, Aparicio A, Zhao D. Immune Checkpoint B7-H3 is a Therapeutic Vulnerability in Prostate Cancer Harboring PTEN and TP53 Deficiencies. Sci Transl Med. 15(695):eadf6724, 5/2023. Epub 2023 May. PMID: 37163614. PMCID: PMC10574140.
Li H, Gigi L, Zhao D. CHD1, a multifaceted epigenetic remodeler in prostate cancer. Frontiers in Oncology. 1/2023. 13. doi: 10.3389/fonc.2023.1123362. Epub 2023 Jan. PMID: 36776288. PMCID: PMC9909554.
2020-2022
Li H, Wang Y, Lin K, Venkadakrishnan VB, Bakht M, Shi W, Meng C, Zhang J, Tremble K, Liang X, Song JH, Feng X, Van V, Deng P, Burks JK, Aparicio A, Keyomarsi K, Chen J, Lu Y, Beltran H, Zhao D. CHD1 promotes sensitivity to Aurora kinase inhibitors by suppressing interaction of AURKA with its coactivator TPX2. Cancer Res. 2022 Jun 30:can.22.0631. doi: 10.1158/0008-5472.CAN-22-0631. Epub ahead of print. PMID: 35771632. PMCID: PMC9444962
Deng Y, Xia X, Zhao Y, Zhao Z, Martinez C, Yin W, Yao J, Hang Q, Wu W, Zhang J, Yu Y, Xia W, Yao F, Zhao D, Sun Y, Ying H, Hung MC, Ma L. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. Nat Commun. 2021 Dec 6;12(1):7041. doi: 10.1038/s41467-021-27349-7. PMID: 34873175. PMCID: PMC8649069.
Zhao D#, Cai L#, Lu X#, Liang X, Li J, Chen P, Ittmann MM, Shang X, Jiang S, Li H, Meng C, Flores I, Song JH, Horner JW, Lan Z, Wu CJ, Li J, Chang Q, Chen KC, Wang G, Deng P, Spring DJ, Wang YA, DePinho RA. Chromatin Regulator, CHD1, Remodels Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer. Cancer Discov. 2020 May 8; CD-19-1352. doi: 10.1158/2159-8290. PMID: 32385075. PMCID: PMC7483306.
2017-2019
Chen P, Zhao D, Li J, Liang X, Li J, Chang A, Henry V, Lan Z, Spring DJ, Rao G, Wang Y, DePinho RA. Symbiotic Macrophage-Glioma Cell Interactions Reveal Synthetic Lethality in PTEN-Null Glioma. Cancer Cell. 2019 Jun 10;35(6):868-884.e6. PMID: 31185211. PMCID: PMC6561349.
Wang G#, Zhao D#, Spring DJ, DePinho RA. Genetics and Biology of Prostate Cancer. Genes & Dev. 2018 Sep 1;32(17-18):1105-1140. PMID: 30181359 PMCID: PMC6120714.
Zhao D, DePinho RA. Synthetic Essentiality: Targeting tumor suppressor deficiencies in cancer. BioEssays. 2017 Aug;39(8). PMID: 28675450. PMCID: PMC8610080.
Zhao D, Lu X, Wang G, Lan Z, Liao W, Li J, Liang X, Chen JR, Shah S, Shang X, Tang M, Deng P, Dey P, Chakravarti D, Chen P, Spring DJ, Navone NM, Troncoso P, Zhang J, Wang YA, DePinho RA. Synthetic essentiality of chromatin remodeling factor CHD1 in PTEN-deficient cancer. Nature. 2017; 542(7642): 484-488. PMID: 28166537. PMCID: PMC5448706.